1,504
Views
1
CrossRef citations to date
0
Altmetric
Case Report

Severe immunochemotherapy-induced toxicities in a patient with dyskeratosis congenita and literature review

, &

References

  • AlSabbagh MM. Dyskeratosis congenita: a literature review. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 2020;18:943–967. doi: 10.1111/ddg.14268.
  • Grill S, Nandakumar J. Molecular mechanisms of telomere biology disorders. J Biol Chem. 2020;296:100064), PMID: 33482595. doi: 10.1074/jbc.REV120.014017
  • Niewisch MR, Savage SA. An update on the biology and management of dyskeratosis congenita and related telomere biology disorders. Expert Rev Hematol. 2019;12:1037–1052. PMID: 31478401 doi: 10.1080/17474086.2019.1662720
  • Alter BP, Giri N, Savage SA, et al. Cancer in the National Cancer Institute inherited bone marrow failure syndrome cohort after fifteen years of follow-up. Haematologica. 2018;103:30–39. PMID: 29051281 doi: 10.3324/haematol.2017.178111
  • Gerbing RB, Alonzo TA, Sung L, et al. Shorter Remission Telomere Length Predicts Delayed Neutrophil Recovery After Acute Myeloid Leukemia Therapy: A Report From the Children’s Oncology Group. J Clin Oncol. 2016;34:3766–3772. PMID: 27354474 doi: 10.1200/JCO.2016.66.9622
  • Savage SA. Dyskeratosis Congenita. University of Washington, Seattle Available from: https://www.ncbi.nlm.nih.gov/sites/books/NBK22301/.
  • Lee J-J, Nam C-E, Cho S-H, et al. Telomere length shortening in non-Hodgkin’s lymphoma patients undergoing chemotherapy. Ann Hematol. 2003;82:492–495. doi: 10.1007/s00277-003-0691-4.
  • Shay JW, Wright WE. Telomeres and telomerase: three decades of progress. Nat Rev Genet. 2019;20:299–309. doi: 10.1038/s41576-019-0099-1.
  • Roake CM, Artandi SE. Regulation of human telomerase in homeostasis and disease. Nat Rev Mol Cell Biol. 2020;21:384–397. PMID: 32242127 doi: 10.1038/s41580-020-0234-z
  • Dokal I, Vulliamy T, Mason P, et al. Clinical utility gene card for: Dyskeratosis congenita – update 2015. Eur J Hum Genet. 2015;23:558–558. doi:10.1038/ejhg.2014.170
  • Alter BP, Giri N, Savage SA, et al. Cancer in dyskeratosis congenita. Blood. 2009;113:6549–6557. PMID: 19282459 doi: 10.1182/blood-2008-12-192880
  • Agrusa JE, Bertuch AA, DiNardo CD, et al. Severe therapy-related toxicities after treatment for Hodgkin lymphoma due to a pathogenic TERT variant and shortened telomeres. Pediatr Blood Cancer. 2019;66:e27779. PMID: 31050187 DOI: 10.1002/pbc.27779
  • Nakamura K, Terai S, Ohbatake Y, et al. [A Case of Stage ⅣRectal Cancer with Dyskeratosis Congenita]. Gan To Kagaku Ryoho. 2019;46:515–517.
  • Walsh MF, Sacca R, Wildman T, et al. Pathogenic Loss-of-Function Germline TERT Mutations in Patients With Solid Tumors. JCO Precision Oncology. 2019;3:1–5. doi:10.1200/PO.19.00230
  • Sadamoto A, Hyodo M, Hinohira Y, et al. A Case of Dyskeratosis Congenita Complicated by Tongue Cancer. Pract Otorhinolaryngol (Basel). 1999;92(3):253–257.
  • Li F, Li W, Qiao X, et al. Clinical features of dyskeratosis congenita in mainland China: case reports and literature review. Int J Hematol. 2019;109:328–335. doi: 10.1007/s12185-018-02582-x.
  • Olson TS, Myers KC. Dyskeratosis congenita and other telomere biology disorders - UpToDate. Dyskeratosis congenita and other telomere biology disorders. Available from: https://www.uptodate.com/contents/dyskeratosis-congenita-and-other-telomere-biology-disorders#H2790077520.